Cancer Treatment Research: Developments in Oncology, cartea 2
Editat de J. Aisner, P. Changen Limba Engleză Paperback – 15 oct 2011
Din seria Developments in Oncology
- 5% Preț: 353.45 lei
- 5% Preț: 377.07 lei
- 5% Preț: 345.69 lei
- 5% Preț: 1074.75 lei
- 5% Preț: 353.62 lei
- 5% Preț: 1103.07 lei
- 5% Preț: 3118.93 lei
- 5% Preț: 363.85 lei
- 5% Preț: 367.04 lei
- 5% Preț: 1389.15 lei
- 5% Preț: 367.79 lei
- 5% Preț: 1079.77 lei
- 5% Preț: 360.97 lei
- 15% Preț: 592.33 lei
- 5% Preț: 1396.84 lei
- 5% Preț: 1096.43 lei
- 5% Preț: 367.04 lei
- 5% Preț: 1387.38 lei
- 5% Preț: 708.59 lei
- 5% Preț: 698.91 lei
- 5% Preț: 1395.26 lei
- 5% Preț: 704.13 lei
- 5% Preț: 360.26 lei
- 5% Preț: 1394.36 lei
- 5% Preț: 1075.45 lei
- 5% Preț: 3758.19 lei
- 5% Preț: 1078.35 lei
- 5% Preț: 1086.60 lei
- 5% Preț: 1390.62 lei
- 5% Preț: 1410.11 lei
- 5% Preț: 1092.13 lei
Preț: 361.17 lei
Preț vechi: 380.17 lei
-5% Nou
Puncte Express: 542
Preț estimativ în valută:
69.11€ • 72.71$ • 57.22£
69.11€ • 72.71$ • 57.22£
Carte tipărită la comandă
Livrare economică 14-28 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9789400988651
ISBN-10: 9400988656
Pagini: 292
Ilustrații: 288 p.
Dimensiuni: 155 x 235 x 15 mm
Greutate: 0.41 kg
Ediția:Softcover reprint of the original 1st ed. 1980
Editura: SPRINGER NETHERLANDS
Colecția Springer
Seria Developments in Oncology
Locul publicării:Dordrecht, Netherlands
ISBN-10: 9400988656
Pagini: 292
Ilustrații: 288 p.
Dimensiuni: 155 x 235 x 15 mm
Greutate: 0.41 kg
Ediția:Softcover reprint of the original 1st ed. 1980
Editura: SPRINGER NETHERLANDS
Colecția Springer
Seria Developments in Oncology
Locul publicării:Dordrecht, Netherlands
Public țintă
ResearchCuprins
1: New Approaches to the Diagnosis and Classification of the Non-Hodgkin’s Lymphomas.- Lymphomas Originating from B Lymphocytes.- Localization of T Cells in Nodular Lymphomas Nodes.- Well Differentiated Lymphomas.- Intermediate Differentiation.- Burkitt’s Lymphomas.- Lymphomas of T-Cell Origin.- Large Cell Lymphomas.- Summary.- 2: Staging and Treatment of Non-Hodgkin’s Lymphomas.- Staging of Non-Hodgkin’s Lymphomas.- Radiology and Nuclear Medicine Studies.- Scans.- Other Tests.- Treatment of Non-Hodgkin’s Lymphomas.- Chemotherapy.- Conclusions and Recommendations.- 3: Current Issues in the Management of Patients with Hodgkin’s Disease.- Combined Modality Approach to Hodgkin’s Disease.- Complications of Treatment.- Thoughts for the Future.- 4: The Role of Radiation Therapy in the Management of Cancer of the Head and Neck.- Therapeutic Alternatives According to Site.- Equipment for Radiotherapy.- Factors Determining Response to Radiotherapy.- Local Failure of Treatment.- Combined Modality Treatment.- Summary.- 5: Systemic Chemotherapy in Advanced Head and Neck Cancer.- Single Agent Chemotherapy.- Combination Chemotherapy.- Other Areas of Investigation.- Conclusion.- 6: Carcinoma of the Thyroid.- Epidemiology.- Pathology.- Pathogenesis.- Treatment of Well Differentiated Thyroid Carcinomas.- Cytotoxic Drug Therapy.- Medullary Carcinoma of the Thyroid.- Summary.- 7: Computed Tomography in the Evaluation of Abdominal Malignancy.- Clinical Applications.- Summary.- 8: Management of Gastric and Pancreatic Cancer.- Gastric Carcinoma.- Cancer of the Pancreas.- 9: Chemotherapeutic Management of Bladder Cancer.- Indications for Chemotherapy.- Combination Chemotherapy for Transitional Cell Carcinoma of the Bladder.- Conclusions and Prospectus.- 10: Mammography.-Historical Perspective.- Radiation Dosage.- Indications for Mammography.- Mammographic Features of Breast Cancer.- Differential Diagnosis of Breast Cancer on Mammography.- Mammographic Needle Localization.- Specimen Radiography.- Summary.- 11: Breast Parenchymal Patterns on Mammography and Their Relationship to Carcinoma.- Classification.- Correlation of Classification and Cancer.- Prevalent Versus Incident Carcinomas.- Correlation of Parenchymal Patterns with Histopathology.- Conclusions.- 12: Initial Management of Carcinoma of the Breast with Radiation Therapy Instead of Mastectomy.- Radiologic Basis for Therapy.- Principles of Primary Radiation Therapy.- Results of Primary Radiotherapy.- Complications of Radiotherapy.- Relationship of Primary Radiation to Adjuvant Chemotherapy.- Conclusions.- 13: The Surgical Treatment of Primary Breast Cancer.- The Radical Mastectomy.- Treatment of Axillary Nodes.- Predictive Value of Axillary Lymph Nodes.- Lesser Surgical Procedures.- Multicentric Breast Cancer.- Investigative Surgical Approach.- Adjuvant Chemotherapy.- Conclusion.- 14: Clinical Applications of Cell Kinetics to Chemotherapy of Human Malignancy.- Cell Kinetics and Prognosis.- Chemotherapeutic Perturbation of Cell Population Kinetics.- Scheduling for Normal and Tumor Cell Response.- Summary.- 15: Adjuvant Therapy in Childhood Neoplasms — An Overview.- Wilms’ Tumor.- Rhabdomyosarcoma.- Osteosarcoma.- 16: An Overview of Adjuvant Therapy in Man.- The Management of Systemic Cancer.- Early Treatment vs Late Treatment.- How to Differentiate Systemic from Local Cancer.- Which Modality of Cancer Treatment is the “Adjuvant”?.- The Requirements for Inclusion of Chemotherapy in the.- Adjuvant Therapy Lessons from the Treatment of Acute Leukemia.- Treatment of thePatient Who Has No Evidence of Residual Disease.- Summary.- 17: An Overview of Unconventional (Fraudulent) Treatments of Cancer.- Nutrition and Cancer.- Nutritional Misinformation.- Why Are People So Vulnerable to Exploitation in the Field of Nutrition.- The “Freedom of Choice” Argument is a Consumer.- The Unscrupulous and the Misguided Physician.- The Testimonial, the Anecdote, and the Placebo Effect.- The “Terminal” Argument.- The Unconventional (Fraudulent) Treatments for Cancer.- Laetrile.- Why Do People Place Their Lives, or the Lives of Their Loved Ones on a Treatment Which is Generally Rejected as a Fraud by Almost Everyone Trained and Experienced in Cancer Research and Treatment?.- How Unconventional (Fraudulent) Treatments of Cancer are Successfully Promoted — How Laypeople are Deceived — Laetrile as an Example.- Who Makes, or Should Make, Scientific Policy?.- Contributing Authors.